FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

CONSHOHOCKEN, Pa., Jan. 6, 2026 /PRNewswire/ -- Tiger BioSciences, a leader in regenerative medicine and tissue innovation, today announced the acquisition of Platelet-Rich Fibrin Matrix (PRFM) ...

Medicare’s upcoming wound care policy changes will require a mandatory four-week standard treatment trial before covering advanced therapies, potentially delaying life-saving treatments New evidence ...

SALEM – People with diabetes suffering from hard-to-heal foot ulcers now have access to a groundbreaking new treatment available at Salem Regional Medical Center’s (SRMC) Wound Healing Center (WHC).

Among younger American adults, death from chronic disease actually increased — a rarity among high-income countries, a new report shows. By Nina Agrawal Chronic diseases like heart disease, cancer and ...

The global chronic wound care market is estimated to be valued at USD 18.6 billion in 2025 and is projected to reach USD 26.7 billion by 2035, registering a compound annual growth rate (CAGR) of 3.7% ...

Chronic wounds, which result from conditions like diabetes, venous insufficiency, or prolonged pressure, significantly impact quality of life when healing is delayed. These wounds fail to progress ...

As the average age of the global population increases, healthcare systems must adapt to treating chronic wounds in elderly patients. Current wound treatments overlook the unique characteristics of ...

Fibroblasts play a central role in maintaining healthy tissue structures, as well as in the development and progression of diseases. For a long time, these specialized connective tissue cells were ...

If you’re searching for advanced wound care in Tucson, look no further than Dr. Jeff Monash and his expert team at the Wound Center of Tucson. As a leading board-certified wound care specialist, Dr.

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.